Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Another 15 concessionary prices agreed for July

The Department of Health and Social Care and the National Assembly for Wales have agreed concessionary prices for a further 15 items for July 2018 prescriptions.

An initial 13 items received concessionary prices for July on Wednesday.

Drug
Strength
Form
Price
Amisulpride
50mg
tablets (60)
£6.00
Amisulpride
200mg
tablets (60)
£14.00
Bicalutamide
50mg
tablets (28)
£12.40
Co-codamol
30mg/500mg
capsules (100)
£4.52
Doxazosin
4mg
tablets (28)
£0.85
Nicorandil
10mg
tablets (60)
£3.70
Nicorandil
20mg
tablets (60)
£6.00
Orlistat
120mg
capsules (84)
£25.00
Propylthiouracil
50mg
tablets (56)
£38.00
Sodium valproate
500mg
gastro-resistant tablets (100)
£15.40
Sumatriptan
50mg
tablets (6)
£4.21
Sumatriptan
100mg
tablets (6)
£5.05
Tadalafil
5mg
tablets (28)
£45.00
Tolterodine
2mg
tablets (56)
£3.20
Topiramate
100mg
tablets (60)
£14.00

Do these prices reflect the ones you have paid in July so far?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD005442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel